Recent Updates
Recently added Catalysts

MK0493

Phase 2

Obesity | Small molecule | Metabolic |Merck & Company, Inc.|Last Updated: Nov 14, 2019

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials2
Total Enrollment173
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00482196To Study Different Levels of MK0493 for Safety, Efficacy, and Tolerability in Obese Patients (0493-017)(COMPLETED)PHASE2 COMPLETED 173Jul 1, 2005Mar 1, 2006Apr 28, 2015 -
NCT00482638Study of Safety, Tolerability and Efficacy of MK0493 in Obese Patients (0493-008)(COMPLETED)PHASE2 COMPLETED -May 12, 2004Oct 29, 2004Nov 14, 2019 -
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
MK0493DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range21 Years — 65 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Patient is between 21 and 65 years of age Exclusion Criteria: * HIV positive as determined by medical history * Patient is pregnant, lactating or plans to become pregnant * Patient has undergone surgical treatment for obesity * Patient has undergone a surgical procedure with...

Unlock Eligibility Criteria